In a 28‑year‑old patient with lichen sclerosus and asthma who has a periorbital rash that did not respond to Tobradex (tobramycin/dexamethasone) eye ointment and is only minimally controlled with Protopic (tacrolimus) ointment, what is the recommended management?

Management of Periorbital Rash in a Patient with Lichen Sclerosus and Asthma

Given the minimal response to Protopic (tacrolimus) and failure of Tobradex, this periorbital rash likely represents atopic dermatitis or a lichenoid eruption requiring escalation to short-term topical corticosteroids combined with topical antihistamines, followed by consideration of topical ciclosporin drops as a corticosteroid-sparing agent if symptoms persist beyond 2-4 weeks. 1

Immediate Management Approach

First-Line Escalation Therapy

• Initiate short-term ocular topical corticosteroids such as preservative-free dexamethasone 0.1%, prednisolone 0.5%, or hydrocortisone 0.335% eyedrops for moderate-to-severe periorbital dermatitis that has failed tacrolimus 1

• Add topical antihistamines (e.g., olopatadine twice daily for up to 4 months, or ketotifen twice daily) if not previously tried, as these are recommended for mild-to-moderate ocular surface disorders 1

• Continue tacrolimus 0.1% ointment to lid margins if tolerated, as it remains a recommended treatment for periorbital dermatitis in adults, though you should discontinue if ineffective after 2-4 weeks of appropriate use 1, 2

Critical Caveat About Tobradex

Tobradex (tobramycin/dexamethasone) is an antibiotic-steroid combination designed primarily for bacterial conjunctivitis, not inflammatory dermatologic conditions 3. The failure to respond suggests this is not an infectious process but rather an inflammatory dermatosis requiring different therapeutic targeting.

Corticosteroid-Sparing Strategy

Early Introduction of Steroid-Sparing Agents

• Commence topical ciclosporin drops early (0.1% or 0.05%) at the same time as corticosteroid drops to facilitate corticosteroid tapering and avoid prolonged steroid exposure beyond 8 weeks 1

• Consider combination therapy with tacrolimus ointment and ciclosporin drops for treatment-resistant periorbital disease 1

Duration and Tapering

• Treat with corticosteroids until symptoms improve to Grade 1, then taper over 3 weeks 1

• Avoid prolonged corticosteroid use (>8 weeks) due to significant risk of serious ocular adverse effects including glaucoma, cataracts, and skin atrophy 1, 4

Differential Diagnosis Considerations

Lichenoid Eruption vs. Atopic Dermatitis

Given the patient's lichen sclerosus, consider whether this represents:

• Lichenoid disease: Characterized by violaceous papules/plaques, typically responding to high-potency topical steroids (clobetasol 0.05% or fluocinonide 0.05%) or tacrolimus 0.1% ointment 1

• Atopic dermatitis: More common in patients with asthma (part of the atopic triad), presenting with erythematous, pruritic patches 1, 2

The minimal response to tacrolimus suggests this may be more severe inflammatory disease requiring corticosteroid intervention 1, 2.

Important Safety Considerations

Tacrolimus-Specific Warnings

• Avoid tacrolimus in periorbital area if causing local irritation or if ineffective after 2-4 weeks of appropriate twice-daily application 1, 4

• Warn about eye contact: Patients must avoid getting tacrolimus in the eyes and practice aggressive hand washing after application 4

• Long-term safety concerns: While rare, post-marketing cases of lymphoma and skin cancer have been reported with tacrolimus, though causality is not established 4

Sun Protection

• Limit sun exposure during treatment with tacrolimus, as UV light can increase risk of adverse effects 4

• Do not use UV light therapy concurrently with tacrolimus 4

When to Refer to Dermatology/Ophthalmology

Dermatology Referral Indications

• Consider patch testing if unresponsive to topical treatment, to rule out contact dermatitis 1

• Refer if severe symptoms (extensive body surface area involvement, significant quality of life impairment) 1

Ophthalmology Referral Indications

• Urgent referral if visual changes occur or if requiring prolonged topical corticosteroids (>8 weeks) 1

• Consider for ciclosporin initiation and monitoring for ocular complications 1

Alternative Systemic Options (If Topical Therapy Fails)

If the periorbital rash represents lichenoid disease unresponsive to topical therapy:

• Oral antihistamines for symptomatic relief 1

• Short course of oral prednisone (dose and duration based on severity) for moderate-to-severe disease 1

• Steroid-sparing immunosuppressants such as azathioprine, hydroxychloroquine, methotrexate, or mycophenolate mofetil for refractory cases 1

• Doxycycline with nicotinamide as an alternative anti-inflammatory approach 1

Follow-Up Protocol

• Reassess at 2 weeks to evaluate response to corticosteroid therapy 1

• If no improvement after 6 weeks, consider biopsy to confirm diagnosis and rule out other conditions 1

• Monitor for corticosteroid side effects including skin atrophy, telangiectasia, and ocular complications if treatment extends beyond 4 weeks 1, 4